Study investigates management strategies for intermediate to high-risk prostate cancer

“We [at GenesisCare] would be really interested in looking at strategies to identify men that we think are aggressive but localized and offer them a chance to do a shorter course hormonal therapy, which is going to substantially improve quality of life without losing on the efficacy end,” says Bridget F. Koontz, MD.

In this video, Bridget F. Koontz, MD, discusses the background, findings, and takeaways of the study, “Five year results of short course complete androgen blockade with abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high risk prostate cancer,” presented recently at the 2021 American Society for Radiation Oncology Annual Meeting. She also reports updates in GenesisCare technologies related to prostate cancer. Koontz is a radiation oncologist, US chief medical officer, and deputy global chief medical officer for GenesisCare.

Related Videos
Dr. Thomas Hutson in an interview at the ASCO annual meeting
Blur image of hospital corridor | Image Credit: © zephyr_p -
Dr. Michael Stifelman in an interview with Urology Times
Woman talking with doctor | Image Credit: © s_l -
© 2023 MJH Life Sciences

All rights reserved.